Shenzhen Chipscreen Biosciences Co (688321) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Chipscreen Biosciences Co (688321) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥2.25 Million ≈ $328.69K USD) by net assets (CN¥1.66 Billion ≈ $242.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688321 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Shenzhen Chipscreen Biosciences Co - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Shenzhen Chipscreen Biosciences Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shenzhen Chipscreen Biosciences Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Chipscreen Biosciences Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fila Holdings Corp
KO:081660
|
0.099x |
|
Byline Bancorp Inc
NYSE:BY
|
0.043x |
|
Supreme Petrochem Limited
NSE:SPLPETRO
|
-0.019x |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
-0.105x |
|
Kraken Robotics Inc
V:PNG
|
-0.046x |
|
SKYWORTH GRP UNSP.ADR/30
F:KYW0
|
N/A |
|
Devyani International Limited
NSE:DEVYANI
|
0.095x |
|
Arteche Lantegi Elkartea SA
MC:ART
|
0.249x |
Annual Cash Flow Conversion Efficiency for Shenzhen Chipscreen Biosciences Co (2016–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Chipscreen Biosciences Co from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Shenzhen Chipscreen Biosciences Co market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.58 Billion ≈ $231.36 Million |
CN¥76.13 Million ≈ $11.14 Million |
0.048x | +157.49% |
| 2023-12-31 | CN¥1.71 Billion ≈ $250.21 Million |
CN¥-143.21 Million ≈ $-20.96 Million |
-0.084x | -404.81% |
| 2022-12-31 | CN¥1.58 Billion ≈ $230.57 Million |
CN¥43.30 Million ≈ $6.34 Million |
0.027x | -68.78% |
| 2021-12-31 | CN¥1.42 Billion ≈ $207.44 Million |
CN¥124.78 Million ≈ $18.26 Million |
0.088x | +40.45% |
| 2020-12-31 | CN¥1.49 Billion ≈ $218.59 Million |
CN¥93.62 Million ≈ $13.70 Million |
0.063x | +469.17% |
| 2019-12-31 | CN¥1.45 Billion ≈ $211.64 Million |
CN¥-24.55 Million ≈ $-3.59 Million |
-0.017x | -135.54% |
| 2018-12-31 | CN¥476.90 Million ≈ $69.79 Million |
CN¥22.78 Million ≈ $3.33 Million |
0.048x | +688.32% |
| 2017-12-31 | CN¥450.55 Million ≈ $65.93 Million |
CN¥2.73 Million ≈ $399.54K |
0.006x | -97.84% |
| 2016-12-31 | CN¥213.40 Million ≈ $31.23 Million |
CN¥59.77 Million ≈ $8.75 Million |
0.280x | -- |
About Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more